Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 6/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 5/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2538651 | 0.81 | MMP8 (0.46) | KDM1AMMP8HSD17B10 | |
| SCHEMBL493491 | 0.72 | SLC6A4 (0.44) | KDM1ADPP4MMP8 | |
| SCHEMBL9516925 | 0.67 | LMNA (0.68) | KDM1AMMP8HSD17B10 | |
| SCHEMBL7280926 | 0.67 | LMNA (0.68) | KDM1AMMP8HSD17B10 | |
| SCHEMBL26132257 | 0.66 | AGTR2 (0.58) | AGTR2DPP8DPP7 | |
| SCHEMBL17352193 | 0.66 | TACR1 (0.53) | AGTR2DPP4 | |
| SCHEMBL30842270 | 0.66 | HSD17B10 (0.51) | KDM1AMMP8HSD17B10 | |
| SCHEMBL6232052 | 0.66 | DPP4 (0.56) | DPP4ACELTA4HDPP8DPP9 | |
| SCHEMBL6232055 | 0.66 | DPP4 (0.56) | DPP4ACELTA4HDPP8DPP9 | |
| SCHEMBL30069469 | 0.65 | HSD17B10 (0.50) | MMP8HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119633-B2 | N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | AGTR2 696/4885KDM1A 2343/4885DPP4 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.